Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of NBP608 vs Zostavax in Healthy Adults 50+
NCT03120364Phase 3Completed
- Sponsor
- SK Chemicals
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NBP608 in herpes zoster (HZ) (2 arms), sponsored by SK Chemicals. Primary endpoints: Geometric Mean Ratio of VZV antibody titer measured by gpELISA at 6 weeks and Geometric Mean Ratio ratio of NBP608 to Zostavax measured by gpELISA at 6 weeks. Started Sep 2015; status: completed.
02
Drugs
NBP608
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03120364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120364.